These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 22081725)

  • 1. Determination of meropenem penetration into the lung from Sparse data.
    Kees MG; Lodise TP; Drusano GL
    Antimicrob Agents Chemother; 2011 Dec; 55(12):5959-61. PubMed ID: 22081725
    [No Abstract]   [Full Text] [Related]  

  • 2. Penetration of meropenem into epithelial lining fluid of patients with ventilator-associated pneumonia.
    Lodise TP; Sorgel F; Melnick D; Mason B; Kinzig M; Drusano GL
    Antimicrob Agents Chemother; 2011 Apr; 55(4):1606-10. PubMed ID: 21300830
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Elution and antibacterial activity of meropenem from implanted acrylic bone cement.
    Solomon AW; Stott PM; Duffy K; Kumar PG; Holliman RE; Bridle SH
    J Antimicrob Chemother; 2010 Aug; 65(8):1834-5. PubMed ID: 20519357
    [No Abstract]   [Full Text] [Related]  

  • 4. Multicentre open-label randomised controlled trial to compare colistin alone with colistin plus meropenem for the treatment of severe infections caused by carbapenem-resistant Gram-negative infections (AIDA): a study protocol.
    Dickstein Y; Leibovici L; Yahav D; Eliakim-Raz N; Daikos GL; Skiada A; Antoniadou A; Carmeli Y; Nutman A; Levi I; Adler A; Durante-Mangoni E; Andini R; Cavezza G; Mouton JW; Wijma RA; Theuretzbacher U; Friberg LE; Kristoffersson AN; Zusman O; Koppel F; Dishon Benattar Y; Altunin S; Paul M;
    BMJ Open; 2016 Apr; 6(4):e009956. PubMed ID: 27098822
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Meropenem-induced low valproate levels in a cerebral palsy child.
    Okumura LM; Andreolio C; Di Giorgio C; Carvalho PRA; Piva JP
    Braz J Infect Dis; 2017; 21(4):491. PubMed ID: 28343819
    [No Abstract]   [Full Text] [Related]  

  • 6. Meropenem--an advantageous antibiotic?
    Drug Ther Bull; 1996 Jul; 34(7):53-5. PubMed ID: 8791884
    [No Abstract]   [Full Text] [Related]  

  • 7. Pharmacodynamics of meropenem in critically ill patients with ventilator-associated pneumonia.
    Jaruratanasirikul S; Kositpantawong N; Jullangkoon M; Aeinlang N; Wongpoowarak W
    J Med Assoc Thai; 2013 Oct; 96(10):1283-9. PubMed ID: 24350408
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Experience with extended-infusion meropenem in the management of ventilator-associated pneumonia due to multidrug-resistant Acinetobacter baumannii.
    Wang D
    Int J Antimicrob Agents; 2009 Mar; 33(3):290-1. PubMed ID: 19091523
    [No Abstract]   [Full Text] [Related]  

  • 9. Penetration of meropenem into human pancreatic juice.
    Ikawa K; Kondo N; Nakashima A; Yoshizawa K; Morikawa N; Ikeda K; Murakami Y; Ohge H; Sueda T
    Scand J Infect Dis; 2013 May; 45(5):404-6. PubMed ID: 23176150
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Doripenem vs meropenem against Pseudomonas and Acinetobacter.
    Goyal K; Gautam V; Ray P
    Indian J Med Microbiol; 2012; 30(3):350-1. PubMed ID: 22885206
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and efficacy of colistin versus meropenem in the empirical treatment of ventilator-associated pneumonia as part of a macro-project funded by the Seventh Framework Program of the European Commission studying off-patent antibiotics: study protocol for a randomized controlled trial.
    Rosso-Fernández C; Garnacho-Montero J; Antonelli M; Dimopoulos G; Cisneros JM;
    Trials; 2015 Mar; 16():102. PubMed ID: 25872790
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Meropenem-clavulanic acid shows activity against Mycobacterium tuberculosis in vivo.
    England K; Boshoff HI; Arora K; Weiner D; Dayao E; Schimel D; Via LE; Barry CE
    Antimicrob Agents Chemother; 2012 Jun; 56(6):3384-7. PubMed ID: 22450968
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of the pharmacodynamics of meropenem in patients with ventilator-associated pneumonia following administration by 3-hour infusion or bolus injection.
    Jaruratanasirikul S; Sriwiriyajan S; Punyo J
    Antimicrob Agents Chemother; 2005 Apr; 49(4):1337-9. PubMed ID: 15793108
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use of meropenem in the treatment of serious infections in children: review of the current literature.
    Arrieta A
    Clin Infect Dis; 1997 Feb; 24 Suppl 2():S207-12. PubMed ID: 9126695
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intraperitoneal Meropenem for Polymicrobial Peritoneal Dialysis-Related Peritonitis.
    de Fijter CW; Jakulj L; Amiri F; Zandvliet A; Franssen E
    Perit Dial Int; 2016 9-10; 36(5):572-3. PubMed ID: 27659932
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Optimal cefepime and meropenem dosing for ventilator-associated pneumonia patients with reduced renal function: an update to our clinical pathway.
    Kuti JL; Nicolau DP
    J Crit Care; 2010 Mar; 25(1):155-6. PubMed ID: 20189057
    [No Abstract]   [Full Text] [Related]  

  • 17. In vivo efficacy and pharmacokinetics of biapenem in a murine model of ventilator-associated pneumonia with Pseudomonas aeruginosa.
    Yamada K; Yamamoto Y; Yanagihara K; Araki N; Harada Y; Morinaga Y; Izumikawa K; Kakeya H; Hasegawa H; Kohno S; Kamihira S
    J Infect Chemother; 2012 Aug; 18(4):472-8. PubMed ID: 22215228
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Meropenem: a review of its use in the treatment of serious bacterial infections.
    Baldwin CM; Lyseng-Williamson KA; Keam SJ
    Drugs; 2008; 68(6):803-38. PubMed ID: 18416587
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacodynamics of carbapenems for the treatment of Pseudomonas aeruginosa ventilator-associated pneumonia: associations with clinical outcome and recurrence.
    Crandon JL; Luyt CE; Aubry A; Chastre J; Nicolau DP
    J Antimicrob Chemother; 2016 Sep; 71(9):2534-7. PubMed ID: 27272723
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical pharmacokinetics of meropenem in pancreatic juice and site-specific pharmacodynamic target attainment against Gram-negative bacteria: dosing considerations.
    Kondo N; Ikawa K; Murakami Y; Uemura K; Sudo T; Hashimoto Y; Ohge H; Morikawa N; Sueda T
    Pancreatology; 2014; 14(2):95-9. PubMed ID: 24650961
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.